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Résumé de la publication de thèse
Cette thèse a fait l’objet de deux publications peer review :
I. Facteurs associés avec l’infection tuberculose latent chez les requérants d’asile entrant 
dans le canton de Vaud : Une étude transversale dans le canton de Vaud.
Objectifs : Les objectifs de cette étude étaient l’identification des facteurs associés à l’infection 
tuberculeuse latente (ITBL) chez les requérants d’asile récemment arrivés au Canton de Vaud et leur 
utilisation pondérée pour l’élaboration d’un score prédictif qui pourrait permettre la meilleure 
sélection des individus à dépister avec les Interferon Gamma Release Assays (IGRA). 
Méthode : Le protocole de l’étude prévoyait l’inclusion des requérants d’asile de plus de 16 ans, 
récemment arrivés dans deux centre de requérant du canton de Vaud ceux de Sainte-Croix et de 
Crissier. De septembre 2009 à juillet 2010 les requérants d’asile ont bénéficié lors des visites au centre 
de soins infirmier (CSI) d’informations sur l’ITBL et le protocole et les enjeux de l’étude. Les 
requérants d’asile ont d’emblée été informées que leur participation à l’étude n’aurait pas d’impact sur 
le débouché de leur dossier d’asile et qu’il n’y aurait pas de compensation financière à leur 
participation. Après avoir signé le consentement éclairé les requérants d’asile bénéficiaient d’une 
entrevue avec l’infirmière du centre où un questionnaire démographique et médical était remplit. 10cc 
de sang étaient prélevés à la fin de l’entrevue pour l’examen IGRA. Les patients présentant des 
symptômes évocateurs de tuberculose active ou un anamnèse de traitement pour une tuberculose active 
étaient exclus de l’étude et adressés au médecin référant du centre pour une visite médicale. Selon les 
résultats du test T-SPOT.TB (IGRA), les requérants étaient classés en deux groupes : positifs et 
négatifs. Le groupe IGRA positif était adressé au médecin référant. L’analyse statistique des données 
de l’étude a été réalisée par le logiciel STATA 11.2. Les β coefficients de l’analyse multivariée ont été 
combinées pour la création d’un score pronostic dont la puissance de discrimination a été évaluée par 
une courbe ROC. Le protocole de l’étude avait reçu l’aval de la commission d’éthique de l’Université 
de Lausanne. 
Résultats : Durant la période de l’étude, 788 requérants d’asile ont été hébergés dans les deux centres 
de l’étude. 639 avaient plus de 16 ans et 393 d’entre eux ont participé à l’étude (61.50%).  295 
(75.06%) avaient un  IGRA négatif et 98 (24.93%) étaient positifs. A noter que parmi les 98 positifs, 5 
avaient une tuberculose active non détecté précédemment. Les analyses univarié et multivarié ont 
permis d’identifier 6 facteurs associées à l’ITBL : Région d’origine, moyen de transport, état civil, 
âge, toux et antécédent d’exposition à la tuberculose. Le score élaboré en combinant ces 6 facteurs 
présente un AUC de 81% avec une sensibilité de 80%, une spécificité de 70% et des valeurs prédictive 
positive et négative respectivement de 45% et 92% quant un seuil de 13 est utilisé. 
Conclusion : Les requérants d’asile qui immigrent en Suisse proviennent de pays où l’incidence de la 
tuberculose est supérieure à celle des pays de l’Europe occidentale et présentent un risque élevé pour 
l’infection tuberculose latente (ITBL). L’origine comme seul facteur n’est pas suffisant pour stratifier 
le risque d’ITBL et ne peut pas justifier la prescription d’un traitement préventif d’ITBL. 
L’introduction des tests de détection, hautement spécifiques de l’infection au M. tuberculosis tel que 
les IGRA ainsi que le taux élevé de réussite des traitements préventifs de l’infection latente ont ouvert 
la voie à un dépistage précoce de l’ITBL qui compléterait le dépistage de la tuberculose active 
actuellement effectué à la frontière. Afin de mieux cibler le dépistage par ces tests une meilleure 
sélection des individus à dépister est impérative. Elle pourrait se faire en évaluant le score individuel 
de risque ITBL par requérant.  


II. Taux élevé d’adhérence au traitement préventif de l’infection tuberculeuse latente 
prescrit à un collectif de requérants d’asile dans un canton suisse. 
Objectifs: L’efficacité du traitement préventif de l’infection tuberculeuse latente dépend de 
l’adherence du sujet au traitement. Un traitement bien conduit pour une duré prévue est en mesure de 
prévenir l’activation des cas d’infection tuberculeuse latente (ITBL). Le plus grand enjeu dans un 
programme préventif pour la tuberculose est, outre de cibler la détection des individus les plus à risque 
pour l’ITBL, de pouvoir traiter efficacement le collectif dépisté positif. Cette étude évaluait la 
faisabilité d’un traitement préventif court parmi un collectif de requérants d’asile porteurs d’une ITBL 
dans le canton de Vaud. 
Méthode: Nous avons effectué une étude prospective de cohorte parmi des requérants d’asile 
récemment attribués dans le canton de Vaud,  âgés de plus de 16 ans et qui avaient été dépistés positifs 
par IGRA. L’ensemble du collectif selon le protocole de l’étude était adressé au médecin référant afin 
d’exclure une tuberculose active et pour discuter du traitement préventif si le diagnostic d’ITBL était 
confirmé. Lors de la première visite médicale, outre l’examen clinique, un bilan radiologique avec une 
radiographie du thorax et un bilan de la biologie hépatique ainsi qu’un test de dépistage HIV était 
proposé à l’ensemble du collectif. En cas de suspicion clinique ou d’image radiologique suspecte de 
tuberculose active le sujet était adressé pour des examens complémentaires. Les sujets porteurs 
d’ITBL se voyaient proposés, en l’absence de contre indications, un traitement de rifampicine de 
quatre mois. En acceptant de participer à l’étude ils s’engageaient de se présenter à leur contrôle 
médical mensuel où était évaluée l’adhérence au traitement et l’apparition d’effets indésirable ou de 
complications. Si l’adhérence était jugée correcte l’ordonnance du traitement était renouvelée d’un 
mois et le requérant recevait son prochain rendez-vous de contrôle. L’adhérence était considéré 
satisfaisante si le patient était adhérent à son schéma de visites médicales et demandait le 
renouvellement de son ordonnance. Si le requérant d’asile ne se présentait pas à deux contrôles il était 
considéré comme non adhérent et son traitement est suspendu. 
Résultats : Notre collectif comptait 98 sujet présument atteint de ITBL sur la base du test T-SPOT.TB 
ce qui représentait 24.9% du collectif initial. L’âge moyen était de 26.7 ans, 74% était des hommes. La 
majorité étaient des africains: 66 %, 17% étaient asiatiques et les populations balkaniques et de l’ex-
union soviétique étaient représentés à part égale d’huit pourcent. Parmi notre collectif nous n’avions 
pas de sujet immunodéficient notamment HIV positif. Des 98 sujets, 11 ne se sont pas présenté à leur 
visite médicale initiale. La visite médicale initiale a permis la détection de 8 patients porteurs d’une 
tuberculose active, dont cinq ont reçu un traitement antituberculeux, ou d’une autre affection 
pulmonaire non tuberculeuse. Chez deux patients il y avait une contre-indication au traitement 
préventif et deux avaient un anamnèse positif de traitement antituberculeux non précédemment 
déclaré. Le traitement préventif a été prescrit à 74 requérants d’asile. Durant le suivi mensuel trois 
requérants ne se sont pas présentés lors de la première visite de suivi, trois lors de la seconde et sept 
lors de la troisième pour un total de 13 sujets. Chez deux sujets le traitement préventif a du être 
suspendu à cause d’une adhérence problématique secondaire à des abus de substances illégales. Durant 
le suivi, nous n’avons pas eu de sérieuses complications ni d’effets indésirables au traitement qui 
auraient nécessité son arrêt. En final 60/75 des sujets ont achevé leur traitement soit 80% du collectif. 
Conclusion: Malgré la vulnérabilité et la volatilité inhérente à cette population qui est d’ailleurs la 
plus à risqué de réactivation d’une ITBL, cette étude montre que il est possible d’obtenir de taux 
d’adhérence très élevés au traitement préventif. Nous considérons que les conditions qui ont permis 
ces résultats sont la prescription d’un schéma de traitement préventif court, un suivi médico-soignant 
régulier et l’hébergement contrôlée et stable où résidait notre collectif. 
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Factors associated with latent tuberculosis among
asylum seekers in Switzerland: a cross-sectional
study in Vaud County
Apostolos Sarivalasis1*, Jean - Pierre Zellweger2, Mohamed Faouzi3, Oscar Daher4, Charlotte Deslarzes5
and Patrick Bodenmann1
Abstract
Background: Screening and treatment of latent tuberculosis infection (LTBI) in asylum seekers (AS) may prevent
future cases of tuberculosis. As the screening with Interferon Gamma Release Assay (IGRA) is costly, the objective
of this study was to assess which factors were associated with LTBI and to define a score allowing the selection of
AS with the highest risk of LTBI.
Methods: In across-sectional study, AS seekers recently arrived in Vaud County, after screening for tuberculosis at
the border were offered screening for LTBI with T-SPOT.TB and questionnaire on potentially risk factors. The factors
associated with LTBI were analyzed by univariate and multivariate regression.
Results: Among 393 adult AS, 98 (24.93%) had a positive IGRA response, five of them with active tuberculosis
previously undetected. Six factors associated with LTBI were identified in multivariate analysis: origin, travel
conditions, marital status, cough, age and prior TB exposure. Their combination leads to a robust LTBI predictive
score.
Conclusions: The prevalence of LTBI and active tuberculosis in AS is high. A predictive score integrating six factors
could identify the asylum seekers with the highest risk for LTBI.
Keywords: Asylum seeker, Latent tuberculosis infection, Tuberculosis, Risk factors, Predictive score, Interferon
gamma release assay
Background
Most of the asylum seekers entering in Switzerland lived
in countries with higher incidence rate of tuberculosis
than in Western Europe and have a high risk of latent
tuberculosis infection (LTBI) [1]. Persons with LTBI are
at risk of developing an active tuberculosis mostly dur-
ing the first years after infection [2]. A preventive treat-
ment of infected but asymptomatic individuals lowers
the risk of reactivation of latent infection and therefore
decreases the pool of future active tuberculosis in a
population [3]. Those principles are the basis of screen-
ing protocols for the management of individuals exposed
to patients with active tuberculosis. Since the majority of
asylum seekers are young adults the presence of LTBI
among them would point to a recent contamination.
Screening migrants for LTBI and treating those at risk
of reactivation has been proven to be effective [4,5]. As
most cases of active tuberculosis among asylum seekers
occur within 5 years of entering Western countries and
are due to the reactivation of a LTBI, screening and pre-
ventive treatment of LTBI, may be a complement to
the screening for active tuberculosis in destination
countries [6].
The current screening procedure for asylum seekers at
the Swiss border consists on a standardized question-
naire on symptoms associated with tuberculosis, history
of contact or prior treatment for active TB and an evalu-
ation of the risk associated with the incidence in the
country of origin. Migrants with symptoms or high risk
of active tuberculosis are assessed by a physician. Those
* Correspondence: apostolos.sarivalasis@yahoo.com
1Department of Ambulatory Care and Community Medicine (PMU), Rue du
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who are asymptomatic are transferred in a local center
in a county. Screening for LTBI with tuberculin skin test
(TST) was used during several years but was suspended
after a study demonstrated the limited implications of a
positive test result, particularly the weak observance of
the treatment for LTBI by physicians and asylum seekers
with a positive TST [7].
The introduction of Interferon-Gamma Release Assays
(IGRAs) as a screening tool for tuberculosis infection
changed the concept of screening individuals exposed to
active TB and potentially infected [8]. IGRAs are highly
specific, not influenced by prior BCG vaccination or con-
tact with most non-tuberculous mycobacteria. They there-
fore help the physician to restrict the need for further
examinations and prescription of preventive treatment.
Screening asylum seekers born in countries with high
prevalence of tuberculosis upon entering Switzerland
with IGRA is limited by the cost of the test and by the
low number of migrants eligible for preventive treat-
ment. Since individuals with LTBI are asymptomatic a
screening based on clinical approach is not an option.
A better definition of the factors associated with LTBI
and reactivation of infection among asylum seeker might
lower the cost of the screening procedure. The screening
with IGRA of the asylum seekers presenting those fac-
tors could be cost-effective since the proportion of posi-
tive IGRA in this group would be higher than of the rest
of the asylum seeker population. A recent prospective
study from The Netherlands confirms the high rate of
positive IGRA test results in immigrants and demon-
strates that immigrants with a positive test result have
a much higher risk of developing tuberculosis within
two years after entry, irrespective of age and origin [9].
The authors consider the possible usefulness of a pre-
ventive treatment in this population group.
Based on such an assumption, some countries have
introduced a selective screening for groups of asylum
seekers considered at high risk of LTBI and reactivation
[10,11]. The aims of this pilot study were to assess the
prevalence of LTBI among asylum seekers entering Vaud
County and to define the factors associated with latent
infection among them.
Methods
Vaud County is host to 9% of the total Swiss asylum see-
ker population. A cross-sectional study was conducted
in two host centers (Sainte-Croix and Crissier) where
the asylum seekers have to stay after the initial screening
for active TB at the border. For financial and practical
reasons (turnover of entries of AS in Switzerland
and staff holidays), sampling lasted 10 months from
September 2009 to July 2010.
All participating individuals were volunteers aged
above 16 years, lodging in Sainte – Croix and Crissier
host centers. All were recently arrived in Switzerland
and had already been screened at the border for active
tuberculosis two to three months before. They received
detailed information on the study goals and on tubercu-
losis infection and signed a written consent form, trans-
lated in English, French, German, Russian and Arabic.
For those asylum seekers who did not understand those
languages a live translation was provided. The study
was approved by the ethic commission of the University
of Lausanne.
Certified nurses on each of the host center interviewed
the individuals about their origin, demographic, travel
conditions and medical history. Individuals mentioning
a previous tuberculosis treatment were excluded from
the study and addressed to the local health center to
be assessed by a physician. In asylum seekers without a
previous history of tuberculosis, 10ml venous blood was
taken for T-SPOT-TB. The blood tubes were addressed
with same day post mail to the laboratory.
The asylum seeker population was divided in two
groups, positive and negative, according to the T-SPOT.
TB results. Cases with 6 to 8 spots were considered
according to the Swiss recommendations, as positive. No
case was indeterminate.
Asylum seekers with a positive T-SPOT.TB result were
addressed to the local health center for medical assess-
ment. A physician examined them, asking for medical
history of active tuberculosis or TB contact, performed a
clinical examination and ordered a chest X-ray. HIV
screening was proposed to all positive individuals, and
women were offered pregnancy tests.
The asylum seekers presenting with cough, compatible
with tuberculosis symptoms or abnormal chest X-ray
had a sputum examination and culture. All asylum see-
kers with active tuberculosis were treated and excluded
from the study. All asylum seekers with positive T-
SPOT.TB without signs suspect of active TB or abnor-
mal X-ray were considered as carriers of LTBI and were
offered a preventive treatment. The follow-up and feasi-
bility of LTBI preventive treatment is presented in a dif-
ferent paper.
The statistical data analysis was performed using
STATA 11.2 (College Station, Texas 77845 USA). The
data were summarized as mean (sd) for the age and
as number (percentage) for categorical data. Univariate
logistic regression analysis was performed to assess the
association of the demographic, immigration history and
medical factors associated with LTBI. Significant predic-
tors at the level of 20% were used in a backward proced-
ure to elaborate a multivariate model and to develop a
prognostic scoring system to predict LTBI cases.
The β coefficients (β =log (OR)) derived from the
multivariate logistic regression model were used to develop
an overall prognostic scoring system. To simplify the
Sarivalasis et al. BMC Infectious Diseases 2012, 12:285 Page 2 of 7
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calculation of the score, each β- coefficients were multi-
plied by 3 and were rounded to the closest integer. The
score was calculated as the sum of the weighted scores
from the six related factors. The discriminatory power of
the score was assessed with a ROC curve.
Results
Among 788 asylum seekers registered in two dedicated
centers during the study period, 639 were adults over
16 years old. 393 of them agreed to be screened (61.50%
of the eligible population). In this group, 295 (75.06%)
asylum seekers had a negative T.SPOT.TB, and 98
(24.93%) had a positive T-SPOT.TB of which 5 (5.1%)
had active tuberculosis (3 culture-proven) previously not
detected at the border and 2 had already been treated
for active tuberculosis prior to the entry in Switzerland
(Figure 1). The spot distribution is provided on Figure 2
(Figure 2). The characteristic of the 5 cases with active
tuberculosis are shown on Figure 3 (Figure 3). The
remaining 38, 5% did not agree respond to the proposed
screening or left the country before any investigation.
Detailed data on the unscreened collective is scarce but
their median age is of 29.26 years, 25% were women and
their origin distribution is shown on Figure 4.
In the univariate analysis (Table 1) balkanic origin was
set as reference since the tuberculosis incidence rate in
balkanic countries is close to the western European
countries. Associated with LTBI variables were: origin
from FSU and Africa, ground/sea transit pattern, pre-
vious TB exposure and cough. The variables Age, Sex,
Asian origin, being married, the existence of siblings and
offspring as well as prior stay in congregate settings,
addictions and immunosuppression were not associated
with an increased risk of LTBI.
The multivariate logistic regression (Table 2) identified
origin from the Former Soviet Union 12.54 (2.02,
77.9), Asia 2.63 (0.49, 14.12) and Africa 26.11 (5.04,
135.43), ground transit 2.42 (1.34, 4.37), married status 2
(1.01, 3.82), and cough 8.08 (2.63, 24.87) as the major
factors associated with LTBI. Prior TB exposure 1.94
(0.65, 5.72) and age by 10 years 1.37 (0.99, 1.88) were
considered as minor factors related with LTBI because
of their almost significant CI 95% interval.
The values of our predictive score (Figure 5.) ranged
from 2 to 23 (median (11.5), IQR (6.3)). The probability of
having a positive IGRA increases with score value. The
score had a good discriminatory power (AUC=81%) with a
sensitivity of 80%, a specificity of 70%, a PPV of 45% and a
NPV of 92% when using the cutoff-score=13 (Figure 6).
Discussion
The main objectives of this study were to assess the
factors associated with LTBI among asylum seekers
entering Vaud County. A robust score combining six
factors (country of origin, travel conditions, age, marital
status, cough, prior TB exposure) allowed the identifica-
tion of AS with the highest risk of LTBI.
The prevalence of LTBI of 24.9% observed in this
study among asylum seekers is close to the estimates
reported in the literature. Winje and et al. reported a
29% [12] prevalence while Hardy AB and al, reported
38% [13]. Pareek [1] demonstrated that the proportion
of asylum seekers in UK with a positive IGRA was be-
tween 3 and 28%, related to the incidence of tuberculosis
in the home country and Mulder [9] reported a similar
Figure 1 Study flowchart.
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*
Figure 2 Spot distribution among positive IGRA. *During the
study period we followed the actual Swiss Guidelines and the cases
with 6–9 spots were counted as positive. The recent CDC
recommendations differ and propose to consider tests results
between 6 and 9 spots as borderline.
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result with 20% positive QuantiFERON(W)-TB Gold In-
Tube assay among AS.
A striking figure is the detection of 5 subjects with
active tuberculosis that passed undetected through the
border screening performed several weeks before. We as-
sume that these subjects progressed from a recently
acquired infection after border screening according to the
natural history of TB. Considering the fact that the majority
of cases of tuberculosis among asylum seekers are notified
after entry, this is not surprising but underlines the fact that
migrants with complaints or health problems should have
rapid access to health care and tuberculosis diagnosis. A re-
cent study by Ricks [14] highlighted the importance of
LTBI screening and treatment in order to reduce the bur-
den of TB among foreign born individuals in the US.
The multivariate logistic regression permitted to iden-
tify the major factors associated with LTBI. Married
individuals from an African or an FSU country that
crossed multiple borders to reach Switzerland border
and who cough are mostly at risk of being infected. Two
minor factors (age and positive history of TB exposure)
were also highlighted. Using those six factors we elabo-
rated a predictive model for screening asylum seekers
for LTBI resulted in a score with an AUC=81%.
The risk of LTBI increases with age. Indeed the longer
a person lives the greater are the risk of being in contact
with an individual with active TB. The main feature of
using age as LTBI predictor is the presumed time of
infection. Due to their young age and to the travel con-
ditions, frequently in very close contact with other
persons during prolonged periods, we assume that these
individuals have been infected recently.
In our study married individuals also had a higher risk
of being infected with an odd ration of 2.0. This is a
quite interesting finding since demographic data on dis-
ease shows an opposite relation [15]. Although no solid
explanation can be given for this finding our collective
showed a clear association with LTBI.
The prevalence of tuberculosis in the home country is
correlated with a risk of having LTBI. The NICE guide-
lines suggest LTBI screening for all asylum seekers
migrating from countries with a TB prevalence higher
than 50/100.000 [11]. Applying this rule to Switzerland
would mean screening the majority of asylum seekers
and would imply high costs and logistical problems. Due
screened not 
screened total
FSU 20 33 53
Balkan 62 45 107
Asia 127 50 177
Africa 184 118
Figure 4 Distribution of the collective by region of origin.
Figure 5 Predictive score calculation. Example: The score for an
asylum seeker from former Soviet Union, aged 47 without ground
transit, no cough, married with previous exposure to TB is equal to:
7+4.7+2+2=15.7. In such case, screening with IGRA is justified.
* balkanic asylum seekers demostrate similar LTBI/TB prevalence as
native population.
Table 1 Univariate analysis
Factors Positive
n(%)
Negative
n(%)
Odd
ratio
(95% Conf.
interval)
p<0.05
Age , mean(sd) 29.09 27.63 1.02 0.99 , 1.04 0.179
Age (by 10 years) 29.09 27.63 1.18 0.93 , 1.49 0.179
Sex
Male 214 72 1.05 0.62 , 1.76 0.858
Origin
balkanic origin (ref) 54 8 ref. ref. ref.
FSU 12 8 4.5 1.41 , 14.4 0.011
Asia 110 17 1.04 0.42 , 2.57 0.927
Africa 119 65 3.69 1.65 , 8.22 0.001
Ground transit 109 60 2.49 1.54 , 4.02 0.000
Married 124 48 1.34 0.84 , 2.12 0.219
Siblings 243 73 0.53 0.30 , 0.92 0.025
Offspring 111 46 1.45 0.91 , 2.32 0.116
Congregate settings 96 34 1.1 0.68 , 1.78 0.695
Addictions 138 54 1.4 0.88 , 2.21 0.154
Immunosuppresion 19 7 1.3 0.46 , 2.78 0.79
Prev. TB exposure 12 9 2.38 0.97 , 5.84 0.057
Cough 17 12 2.3 1.05 , 5.01 0.036
Active TB Characteristics
N° ORIGIN SEX AGE SPOTS
1 FSU F 47 30-50
2 AFRICA M 18 50-100
3 AFRICA M 24 50-100
4 AFRICA M 20 50-100
5 AFRICA M 20 10-20
Figure 3 Characteristics of cases with active TB.
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to the limited population of this study the independent
evaluation of each country of origin was not possible.
Therefore we studied those countries mainly represented
in the Swiss asylum seeker population. Bias due to the
addition of populations like North Africans (low risk)
and sub Saharan Africans (high risk) to the statistical
analysis could not be avoided. Due to the absence of asy-
lum seeker from Latin American origin in our collective,
we could not assess the risk in this population.
The travel conditions to reach Switzerland were clearly
related to the risk of LTBI infection. Individuals travel-
ling directly to destination using airplane meet fewer
migrants in their journey and therefore have a lower risk
of TB infection. A long and hazardous journey through
several borders using ground and/or sea transportation
increases the risk of TB contacts and infection. Although
the socioeconomic status of the asylum seeker might
influence the travel pattern it is difficult to argue that
ground/sea transit is less expensive than airplane but it
is seems clear that access to airplane is limited to per-
sons with higher socio-economic status and access to
official (or fake) documents.
A previous exposure to TB is an obvious factor related
with LTBI. A personal history of recent exposure to pre-
sumed or confirmed active TB person enhances the risk
of LTBI and its reactivation potential mostly during the
following two years.
That cough was identified as a risk factor for LTBI is
surprising since by definition LTBI is an asymptomatic
infection. This could be due to the fact that smokers
(who are very prevalent in this population group) have a
higher risk of LTBI and tuberculosis than non smokers
[16]. Other plausible explanation for this finding could
be the congregated way of living, especially during win-
ter months in asylum seeker centers with high exposure
to passive smoking as well as the lack of stratification
during statistical analysis between chronic and acute
coughing due to sample limitations. When present,
chronic cough was extensively assessed to rule out dis-
ease while acute coughing was usually self-limited.
The limitations of our study are the local setting, the
inherent characteristics of this mobile population, the
cross sectional design and the voluntary pattern of
enrolment. This study provided a realistic description of
actual collective of asylum seekers arriving in Vaud
county. As the asylum seeker population is randomly
allocated in the different regions of Switzerland, we
assume that this population group was representative
of the demographic details of the whole asylum seeker
population in Switzerland. Nevertheless in this study
Figure 6 The area under the ROC curve (AUC=81%) gives a measure of the discriminative power of the score between the infected
and the control group. The red dot corresponds to the sensitivity/specificity at a cut-off of 13.
Table 2 Multivariate logistic regression
Risk factor Odds
ratio
(95% Conf.
interval)
p<0.05
Age (by 10 years) 1.37 0.99 , 1.88 0.054
Origin
balkanic (ref) ref. ref. ref.
FSU 12.54 2.02 , 77.9 0.007
Asia 2.63 0.49 , 14.12 0.26
Africa 26.11 5.04 , 135.43 0.000
Ground transit 2.42 1.34 , 4.37 0.003
Married 2 1.01 , 3.82 0.038
Prev. TB exposition 1.94 0.65 , 5.72 0.233
Cough 8.08 2.63 , 24.87 0.000
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61% of the recently arrived asylum seeker population
was screened using IGRA qualifying this study as repre-
sentative of the study population. In addition to this,
since no selection was applied to the study population,
the travel condition and characteristics of the asylum
seeker entering Vaud County match those of asylum see-
kers entering in other western European countries. Some
bias could result from the voluntary pattern of enroll-
ment with an over-representation of sick migrants but
this setting was essential for the ethical acceptance of
the study protocol. As the proportion of migrants with
positive IGRAs was similar as in comparable studies,
we assume that this was not a bias. Moreover, among
AS who entered in the centre, the actual number of
eligible persons was lower since many of them left the
territory or were rejected before the enrollment pro-
cedure could be started. We have decided to include
all the asylum seekers that were present on the asylum
seekers registry to the study collective to better de-
scribe the reality. Finally since this study is time and
country specific the collective characteristics are subject
to change over time following the shift in immigration
pattern.
Conclusions
This study highlights the factors associated with LTBI
among asylum seekers entering Vaud County, Switzerland.
The observed prevalence of LTBI (24.9%) matches with
the prevalence from the literature. The prevalence of TB
previously undetected at the border in asylum seekers with
LTBI was also high (5.1%). The factors associated with
LTBI identified in this population (age, origin from FSU,
Asian and African countries, ground transportation; mar-
ried status; prior TB exposure and cough) were com-
bined to create a predictive score of LTBI for asylum
seekers which could be used at border screening. The ap-
plication of this score to an asylum seeker population
could help discriminating those most at risk for LTBI
permitting a limitation of the number of IGRA to be per-
formed in a border screening setting.
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Summary
BACKGROUND: Preventive treatment may avoid future
cases of tuberculosis among asylum seekers. The effective-
ness of preventive treatment depends in large part on treat-
ment completion.
METHODS: In a prospective cohort study, asylum seekers
of two of the Swiss Canton Vaud migration centres were
screened with the Interferon Gamma Release Assay
(IGRA). Those with a positive IGRA were referred for
medical examination. Individuals with active or past tuber-
culosis were excluded. Preventive treatment was offered
to all participants with positive IGRA but without active
tuberculosis. The adherence was assessed during monthly
follow-up.
RESULTS: From a population of 393 adult migrants, 98
(24.9%) had a positive IGRA. Eleven did not attend the ini-
tial medical assessment. Of the 87 examined, eight presen-
ted with pulmonary disease (five of them received a full
course of antituberculous therapy), two had a history of pri-
or tuberculosis treatment and two had contraindications to
treatment. Preventive treatment was offered to 75 individu-
als (4 months rifampicin in 74 and 9 months isoniazid in
one), of whom 60 (80%) completed the treatment.
CONCLUSIONS: The vulnerability and the volatility of
this population make screening and observance of treat-
ment difficult. It seems possible to obtain a high rate of
completion using a short course of treatment in a closely
monitored population living in stable housing conditions.
Key words: rifampicin; tuberculosis; asylum seekers;
LTBI; preventive treatment
Introduction
Latent tuberculosis infection (LTBI) is a widespread con-
dition among asylum seekers born in or who have lived in
countries with a high prevalence of tuberculosis [1]. Per-
sons with LTBI have a known risk of developing active
tuberculosis at a later stage [2] and can be screened by
tuberculin skin testing or by one of the new Interferon
Gamma Release Assays (IGRA), which offer a greater spe-
cificity [3]. Among the persons with positive IGRA, those
most at risk of developing an active infection are children,
immunosuppressed persons and those with recently ac-
quired infection. The highest risk for the development of
tuberculosis among infected persons is during the first few
years following infection. The risk of reactivation, defined
as the progression from latent infection to active disease
can be decreased by preventive treatment [4].
Asylum seekers (AS) from high incidence countries en-
tering in low incidence countries have a higher rate of
LTBI than the local population, therefore some of them
may develop TB after entering the country, by reactivation
from remote infection. In some low incidence countries
AS or migrants are screened for active TB and LTBI upon
entry. In Switzerland AS are screened at the border for act-
ive TB only. Cases with LTBI are not detected and not
offered a preventive treatment so that the possible progres-
sion from infection to disease after entry is not preven-
ted. The treatment of latent tuberculosis infection (LTBI) is
generally considered costeffective and a component of the
strategy towards elimination of tuberculosis in low-incid-
ence countries [5Ð7]. The key features of a cost effective
LTBI screening strategy are proper screening, selection of
persons at highest risk of progression and the completion
of preventive treatment by eligible persons with LTBI who
are expected to follow a long treatment in spite of being
asymptomatic [8].
The low adherence to LTBI treatment is the main challenge
in the preventive strategy. According to various studies the
completion rate of preventive treatment varies from 10%
to 86% [9, 10]. The duration and side effects of preventive
treatment along with the lack of awareness on active tuber-
culosis disease by people with LTBI, and the high social
and economical vulnerability of some population groups
like asylum seekers render adherence to treatment a highly
challenging issue for both the physician and the patient.
No factor seems to reliably predict the adherence to pre-
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ventive treatment [11]. Our study aims to assess the rate
and conditions of adherence to preventive treatment in a
population of asylum seekers with latent tuberculosis infec-
tion recently arrived in Canton Vaud. All aspects regarding
screening results, demography and treatment decision were
described in a separate paper [12].
Methods
We conducted a prospective cohort study to assess the feas-
ibility and adherence of preventive treatment in a popula-
tion of asylum seekers (AS) with LTBI newly arrived in
the Swiss Canton Vaud, who had recently passed a border
screening for the detection of active TB. The AS resided in
two migrant centres at Sainte Ð Croix and Crissier. AS aged
over 16 years were offered a free IGRA screening for LTBI
by T-SPOT.TB (Oxford Immunotec, Abingdon, UK). All
asylum seekers received written information about tubercu-
losis and the aims of the study were translated into five ma-
jor languages (English, French, German, Russian and Ar-
abic). All participants signed a consent form. A translator
was used if needed. The study was approved by the ethics
commission of the University of Lausanne.
The results of IGRAs were categorised as positive, inde-
terminate or negative. An additional SPOT.TB was offered
to AS with an indeterminate result.
AS with a positive test result were referred for further ex-
amination to a physician for the exclusion of active TB
and a decision on preventive treatment. The physician ob-
tained a detailed history of TB exposure or treatment, and
performed a clinical examination. A chest X-ray was taken
and human immunodeficiency virus (HIV) screening was
offered to the IGRA positive participants. AS with suspect
clinical manifestations or abnormal radiological findings
had further investigations including sputum examination.
AS with documented or possible active tuberculosis were
treated according to the current Swiss guidelines [13].
AS with LTBI without evidence of active disease were
offered a preventive treatment according to the current
Swiss recommendation with four months of rifampicin
(first choice) or nine months of isoniazid. The rifampicin
scheme was preferred over the isoniazid because of its sim-
plicity of prescription (no need for vitamin substitution,
short treatment time) and follow up (better tolerance, no
need for routine liver function test assessment, visible urine
colouration) advantages that could enhance compliance
with treatment [6]. We did not use incentives. Adherence
to treatment was evaluated during the monthly visit to
the physician where clinical examination, side effects and
symptom assessment was performed. If normal, the pre-
ventive treatment prescription was renewed. In cases of ab-
normality, blood tests were requested. The treatment was
self-administered but the nurse in charge of the centre met
regularly (if possible daily) with the treated AS and rein-
forced the treatment instructions. If the physician was not
assured of the adherence to the treatment directly observed
treatment (DOT) for a month was prescribed.
The adherence to treatment was considered as satisfactory
if the AS were compliant with all scheduled visits and
asked for a repeat prescription. No tablet count was per-
formed. Individuals who did not attend two of the sched-
uled appointments were considered as non-adherent. The
treatment was suspended in individuals with poor or prob-
lematic adherence.
Results
The screening assay with T-SPOT.TB among 393 adult AS
living in two asylum seeker centres in Canton Vaud re-
vealed positive IGRA results in 98 (24.9%), who were re-
ferred for further medical examination. The mean age of
the AS with LTBI was 27.63 years. 74% were men, 66%
were Africans, and 17% were Asians. Balkanic and former
Soviet Union nationals were both 8% and 8% of the col-
lective. No AS with LTBI had a known immunosuppress-
ive treatment or condition, notably HIV infection.
Of them, 11 did not attend the first scheduled medical eval-
uation. After examination, documented or possible tuber-
culosis or another pulmonary disease was discovered in
8/87 AS (of whom 5 were prescribed an antituberculosis
treatment). Two other patients had a history of prior treat-
ment for active tuberculosis. Of the 77 IGRA positive
asymptomatic individuals with normal chest X-ray, 2 had
counter indications (severe liver disorder and pregnancy)
for preventive treatment (fig. 1).
An LTBI treatment with daily rifampicin for four months
was offered to 74 AS, one received isoniazid for 9 months
due to counter indication to rifampicin. During the follow
up three participants defaulted on the first follow-up visit,
three on the second and seven on the third (total 13 cases).
In two individuals preventive treatment was suspended be-
cause of poor compliance and substance abuse. During the
follow-up, no serious adverse event was observed and no
treatment was interrupted for medical reasons. The final
rate of completion of preventive treatment in our cohort
was 80% (60/75) (fig. 2).
Figure 1
Preventive treatment completion flowchart.
* IGRA = Interferon Gamma Release Assay
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Discussion
In this prospective study, the rate of adherence to LTBI pre-
ventive treatment in AS was high with 80%.
One particular feature of the migrant population is the young
mean age, allowing the assumption that many persons with
LTBI must have been infected recently and are therefore still
in a period with a high risk of reactivation. One argument for
this is the fact that migrants arriving in Switzerland by land
or sea/ land travel had a higher rate of LTBI than migrants
travelling by air, indicating that travel conditions were a risk
factor for TB exposure and recent infection (data in a sep-
arate publication) [12]. An indication for this is the fact that
about 75% of all TB observed in AS in Switzerland occurs
more than three months after the border screening, probably
by progression from a recent infection in young adults.
Variable rates of completion are reported with partially
contradictory conclusions regarding the risk factors for
non-adherence. A recent study by Horsburgh et al. reported
that 93.7% of contacts of patients with contagious TB ac-
cept the treatment, whereas only 48.3% of health-care
workers with LTBI detected by routine screening accept it
[9]. A study conducted in Arkansas, US, among patients
treated with isoniazid for LTBI found no correlation
between adherence and age, diagnosis, mode of administra-
tion and duration of treatment, but demonstrated that edu-
cation at the first visit could improve the adherence rate for
further treatment [11]. An analysis conducted by Hirsch-
Moverman et al. in the US and Canada reported rates of
completion from 35% to 64% among contacts with TB,
32% to 61% in prisoners and jail inmates, 22% to 90%
among foreign-born persons, with better rates among re-
cent migrants [10]. Reduction of treatment duration from
six or nine months isoniazid to four months rifampicin was
followed by an increase in the completion rate up to 91%.
Another study by the same group reported a progressive
increase of the completion rate from 37% in 1996Ð1999
to 56.1% in 2002Ð2005 with tighter follow-up of patients
[14]. Trajman et al. confirmed that the overall completion
rate was satisfactory (73%) but that the reduction of the
treatment duration to four months improved the rate of
completion [15]. Similar conclusions were made in a Swiss
study comparing the tolerance and rate of completion in
contacts with LTBI treated with isoniazid for six months
or rifampicin for four months, where the rate of treatment
Figure 2
Monthly assessment and drop outs.
T spot+: Positive T-SPOT.TB, To: initial examination of the
participants, 4R or 9H: Preventive treatment start either four
months of rifampicin or nine months of isoniazid.
interruption because of liver toxicity decreased from 6.1%
to 2% and the rate of treatment completion increased from
74% to 83% [16].
On the contrary, a prospective study conducted in Boston
in 2006 reported a rate of completion of 28.6% (or 33.3%
in recent contacts) [17]. In one study in South Africa, only
20% of children less than five years exposed to parents
with TB completed the preventive treatment [18].
In Switzerland, the results varied. In a study of asylum
seekers screened at the border with tuberculin skin test,
where the subjects with a positive test result were supposed
to have a medical examination and a prescription of pre-
ventive treatment, a large proportion were not prescribed a
treatment or did not complete it [19]. Other reports were
more favourable. A study conducted at the TB Dispensary
in Lausanne reported a global completion rate of 76%
among persons with a positive tuberculin skin test pre-
scribed a preventive treatment with isoniazid for six
months (70% among foreign-born persons, 93% among
foreign workers and 90% in the local population) [20].
Several studies have reported a higher adherence and a
lower rate of adverse events in subjects with LTBI who
were prescribed a short treatment (four months of rifampi-
cin) than among those who had to take a long treatment
(six to nine months of isoniazid) [21, 22]. A report from
the Centre Antituberculeux in Geneva reported an accept-
ance rate of 83% and a completion rate of 67% among
the patients (mostly contacts of TB cases) who started the
treatment with four months of rifampicin [23]. In under-
served population groups, the results are less favourable.
In a study of undocumented migrants in Lausanne, 10/22
persons with a positive IGRA test accepted the preventive
treatment but only 5 completed it [24].
Not prescribing the preventive treatment in infected persons
with a high risk of progression to active tuberculosis can be
considered as a missed opportunity of reducing the pool of
future cases of disease and the transmission of mycobacter-
ia to contacts [25]. In a recent survey in the Netherlands, the
risk of progression to TB among migrants with a positive
IGRA was between 386 and 590/100,000, depending on the
incidence rate in the country of origin [26].
Our study has some limitations. The screening and accept-
ance of preventive treatment for LTBI was voluntary. 39% of
the AS were not screened and some of them may have been
infected and at risk for progression to active tuberculosis dis-
ease [26]. Considering the fact that the screening was offered
to all participants but that this population was extremely mo-
bile, some staying for only few days in the centre, we con-
sider that this pilot study was representative of the target
population. Furthermore, AS were clearly informed that ac-
ceptance or refusal of the proposed screening and preventive
treatment would have no impact on the final decision regard-
ing granting refugee status or not. Also, although the effic-
acy of rifampicin is less extensively documented than iso-
niazid, because of the enhanced adherence to this preventive
treatment scheme this option is a recommended alternative
to the classical isoniazid scheme [16, 27].
Future uncertainties, difficulties of integration and in com-
munication associated with a divergent representation of
health and disease compared with locals are some of the
problems AS need to overcome. The reasons for the high
Original article Swiss Med Wkly. 2013;143:w13860
Swiss Medical Weekly á PDF of the online version á www.smw.ch Page 3 of 6
rate of completion of LTBI treatment in this population
of migrants in spite of social, economical and legal prob-
lems are probably related to the selection of a well-toler-
ated short treatment schedule ( four instead of six or nine
months), a stable environment (accommodation in a shel-
ter with dedicated social workers and nurses caring for in-
mates), regular assessment of the drug intake by the nurses,
close coordination with the medical staff of the referral
hospitals and repeated information about the importance of
treatment). This study demonstrates that a policy of screen-
ing for LTBI and preventive treatment can be implemented
in a migrant population with a high rate of adherence if all
obstacles are carefully considered in advance.
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Figures (large format)
Figure 1
Preventive treatment completion flowchart.
* IGRA = Interferon Gamma Release Assay
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Figure 2
Monthly assessment and drop outs.
T spot+: Positive T-SPOT.TB, To: initial examination of the participants, 4R or 9H: Preventive treatment start either four months of rifampicin or
nine months of isoniazid.
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